Format

Send to

Choose Destination
Mol Cell Pharmacol. 2009 Jan 1;1(4):180-186.

Abuse Potential of Soma: the GABA(A) Receptor as a Target.

Author information

1
Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas.

Abstract

Soma(®) (carisoprodol) is an increasingly abused, centrally-acting muscle relaxant. Despite the prevalence of carisoprodol abuse, its mechanism of action remains unclear. Its sedative effects, which contribute to its therapeutic and recreational use, are generally attributed to the actions of its primary metabolite, meprobamate, at GABA(A) receptors (GABA(A)R). Meprobamate is a controlled substance at the federal level; ironically, carisoprodol is not currently classified as such. Using behavioral and molecular pharmacological approaches, we recently demonstrated carisoprodol, itself, is capable of modulating GABA(A)R function in a manner similar to central nervous system depressants. Its functional similarities with this highly addictive class of drugs may contribute to the abuse potential of carisoprodol. The site of action of carisoprodol has not been identified; based on our studies, interaction with benzodiazepine or barbiturate sites is unlikely. These recent findings, when coupled with numerous reports in the literature, support the contention that the non-controlled status of carisoprodol should be reevaluated.

PMID:
20419052
PMCID:
PMC2858432

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center